Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2011 Jan 31;10(4):679–686. doi: 10.1158/1535-7163.MCT-10-0833

Figure 2. Rapamycin inhibits tumor growth and splenomegaly in Rag1 KO mice that have been implanted with Tg6/λ-MYC lymphoma cells.

Figure 2

Data from one of two experiments are shown. Shown are tumors (A) and spleens (B) collected form the Rag1 KO mice that had been implanted with Tg6/λ-MYC (6M) or λ-MYC (myc) lymphoma cells and then treated with either rapamycin (rapa) or DMSO. The representative spleens from one wild type and two Rag1 KO naive mice are also shown as reference in B (on the top) and D. The weight of tumors (C) and spleens (D) from respective groups are graphed as in Figure 1.